The combination of TRAIL and the Smac mimetic LCL-161 induces an irreversible phenotypic change of MCF-7 breast cancer cells

Small molecules targeting protein–protein interactions for cancer therapy

“… Target Drug Chemical structure Disease Phase NCT number Status Ref. Bcl-2 Venetoclax Chronic lymphocytic leukaemia – – Approved in 2016 20 Navitoclax Chronic lymphocytic leukaemia Ⅱ NCT01087151 Completed 18 APG-2575 Chronic lymphocytic leukaemia Ⅱ NCT05147467 Recruiting 208 Pelcitoclax Neuroendocrine tumours Ⅰ NCT04893759 Recruiting 209 S-64315 Acute myeloid leukaemia Ⅱ NCT04629443 Active, not recruiting 210 Bcl-2 Fadraciclib Leukaemia Ⅱ NCT05168904 Recruiting 211 XIAP Xevinapant Head and neck cancer Ⅲ NCT05386550 Recruiting 212 ASTX660 Solid tumours Ⅱ NCT02503423 Active, not recruiting 213 LCL-161 Breast cancer Ⅱ NCT01617668 Completed 214 GDC-0917 Solid cancers Ⅰ NCT01226277 ...…”